Welcome to our dedicated page for Casi Pharmaceuticals SEC filings (Ticker: CASI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CASI Pharmaceuticals filings document the regulatory record of a foreign private issuer focused on CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases. Recent Form 6-K reports disclose clinical and regulatory matters, including the China Drug Registration Certificate for Thiotepa for Injection, along with material agreements incorporated by reference into Form F-3 registration statements.
The filing record also covers capital-structure events such as convertible-note issuances, governance and management changes, Nasdaq delisting proceedings, and the quotation of the company’s ordinary shares on OTCQB under CASIF. These disclosures address board composition, executive responsibilities, financing terms, listing status, and operating-focus changes for the biopharmaceutical business.
CASI Pharmaceuticals reported closing the second tranche of its US$20 million convertible note financing, issuing a new US$5 million note to ETP Global III Fund LP, a partnership controlled by Dr. Wei-Wu He.
The note matures in 36 months and carries a 12% annual interest rate. At maturity, CASI may choose to convert the principal into ordinary shares at the volume weighted average closing price over the five trading days before maturity, within a conversion price band of US$1 to US$2 per share. The purchaser can also convert at any time from the 91st day after issuance until maturity, using the five-day volume weighted average closing price before its conversion notice, subject to the same US$1 to US$2 per share range.
CASI Pharmaceuticals’ major shareholder Wei-Wu He, Ph.D. and affiliated entities have updated their Schedule 13D to reflect a go-private proposal. The reporting persons collectively beneficially own 3,965,535 ordinary shares, or 19.1% of CASI’s ordinary shares, based on 20,555,873 shares outstanding as of January 8, 2026.
Dr. He submitted an updated preliminary non-binding proposal on January 9, 2026 to acquire, through an acquisition vehicle, all 16,810,338 ordinary shares not held by the reporting persons plus 1,000,000 ordinary shares underlying pre-funded warrants (the “Publicly Held Shares”) for US$1.15 per share in cash, totaling approximately US$20.5 million. The price represents a 30% premium to the average closing price over the last 30 trading days. If completed, CASI’s ordinary shares would be delisted from Nasdaq and registration could be terminated under Section 12(g)(4). The proposal would be financed with a combination of debt and equity, with existing reporting shareholders rolling over their equity.
CASI Pharmaceuticals, Inc. reported closing the first tranche of a planned US$20 million convertible note financing with ETP Global III Fund LP, a partnership controlled by Dr. Wei‑Wu He. The first note has a principal amount of US$5 million, bears interest at 12% per year, and matures in 36 months.
At maturity, CASI may choose to convert the note into ordinary shares at the volume weighted average closing price over the five trading days before maturity, subject to a maximum conversion price of US$2 per share and a minimum of US$1 per share. The purchaser may also convert at any time from the 91st day after issuance until maturity, using a similar five‑day pricing formula. The information in this report is incorporated by reference into CASI’s existing shelf registration statements on Form F‑3.
Panacea investment group disclosed a near-20% stake in CASI Pharmaceuticals and a board appointment. Panacea Venture Healthcare Fund II, L.P. holds 3,550,000 Ordinary Shares (purchased for approximately $6.7 million) and James Huang holds options to buy 111,571 Ordinary Shares, giving the Reporting Persons a combined beneficial interest of 3,661,571 Ordinary Shares, or 19.9% of 18,292,612 shares outstanding. The filing notes Panacea bought 1,500,000 shares from the issuer at $1.5350 per share. The Issuer announced James Huang will join CASI's Board effective October 1, 2025. The Reporting Persons state the position is for investment and reserve the right to buy, sell or pursue corporate actions after review.
CASI Pharmaceuticals, Inc. reports that its Import Drug Registration License for FOLOTYN® in China has expired, following a decision by China’s Center for Drug Evaluation not to grant the company’s May 2025 renewal application. The original license, issued in August 2020, was effective through August 25, 2025, and CASI will immediately cease commercial sales of FOLOTYN® in China under applicable regulations.
The company may continue FOLOTYN® clinical trial activities in China as permitted by relevant authorities and plans to take commercially reasonable measures regarding its FOLOTYN® commercialization plan. CASI remains focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases, with an ongoing Phase 1/2 study in immune thrombocytopenic purpura and an FDA-cleared Phase 1 study in renal allograft antibody-mediated rejection that it plans to initiate in the third quarter of 2025.